Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
Jan 08, 2016 13:10 pm UTC| Business
NORCROSS, Ga., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc...
Portola Pharmaceuticals to Webcast Corporate Update on January 12, 2016
Jan 08, 2016 13:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host an investor webcast to review its recent achievements and corporate and product...
Live Stream Information for MassRoots’ CES Presentation
Jan 08, 2016 13:00 pm UTC| Business
LAS VEGAS, Jan. 08, 2016 (GLOBE NEWSWIRE) -- MassRoots, Inc. (OTCQB:MSRT), one of the largest and fastest growing technology platforms for the cannabis industry, will be presenting on stage at the Consumer Electronics...
Jan 08, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) today announced that it has entered into an exclusive global collaboration agreement with Mylan N.V. (Nasdaq:MYL), (TASE:MYL)...
Hurco Reports Fourth Quarter and Full-Year Results for Fiscal 2015
Jan 08, 2016 13:00 pm UTC| Business
INDIANAPOLIS, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Hurco Companies, Inc. (Nasdaq:HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2015. Hurco recorded net income of $4,804,000, or...
Varonis Announces Date of Fourth Quarter and Full Year 2015 Financial Results Release
Jan 08, 2016 13:00 pm UTC| Business
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq:VRNS), the leading provider of software solutions for unstructured, human-generated enterprise data, today announced that it will report its...
Chiasma Reviews 2015 Accomplishments and Outlines Core Objectives for 2016
Jan 08, 2016 13:00 pm UTC| Business
Ended 2015 with Between $148 Million and $149 Million in Cash, Cash Equivalents and Marketable Securities, Which the Company Believes is Sufficient to Fund Operations at Least Through Mid-2017 Signed Long-Term Commercial...